Molecular diagnostics market to reach USD 28.6B by 2028

Molecular diagnostics market in terms of revenue was estimated to be worth $16.6 Billion in 2023 and is poised to reach $28.6 Billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The increasing availability of funding for R&D activities has fueled advancements in technology, enabling the development of innovative molecular diagnostic solutions. Factors like this together contribute to the growth and development of the molecular diagnostics market, facilitating improved disease detection, personalized treatment approaches, and enhanced patient care.

Molecular diagnostics market major players covered in the report, such as:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Abbott Laboratories (US)
• bioMérieux (France)
• QIAGEN (Netherlands)
• PerkinElmer Inc. (US)
• Myriad Genetics Inc. (US)
• Siemens Healthineers AG (Germany)
• Danaher (US)
• Illumina Inc. (US)
• Becton, Dickinson and Company (US)
• Grifols S.A. (Spain)
• QuidelOrtho Corporation (US)
• Agilent Technologies Inc. (US)
• DiaSorin S.p.A. (Italy)
• Exact Sciences Corporation (US)
• Genetic Signatures (Australia)
• MDx Health (Belgium)
• Biocartis (Belgium)
• TBG Diagnostics Limited (Australia)
• HTG Molecular Diagnostics Inc. (US)
• Vela Diagnostics (Singapore)
• Amoy Diagnostics Co. Ltd. (China)
• ELITechGroup (France)
• Molbio Diagnostics Pvt. Ltd. (India)
• Savyon Diagnostics (Israel)
• Abacus Diagnostica Oy (Finland)
• GeneOmbio Technologies Pvt. Ltd. (India)
• and among others

MarketsandMarkets